MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy
Chyle leak (chylothorax) is a recognised complication following minimally invasive oesophagectomy for oesophageal cancer and may result in prolonged hospital stay, nutritional compromise, and need for additional interventions.
Medium-chain triglyceride (MCT) feeds reduce lymphatic flow as they are absorbed directly via the portal circulation rather than through the thoracic duct. While MCT feeds are commonly used in the management of established chyle leaks, their role in prevention has not been evaluated in a randomised controlled trial.
This single-centre randomised controlled trial will evaluate whether initiating postoperative jejunostomy feeding with MCT-based enteral nutrition reduces the incidence of clinically and biochemically confirmed chyle leak compared with standard enteral feeding in patients undergoing minimally invasive or robotic-assisted oesophagectomy.
Participants will be randomised in a 1:1 ratio to receive either MCT-based feeds or standard jejunostomy feeds starting on postoperative day 1. The primary outcome is the incidence of chylothorax. Secondary outcomes include chest drain output, re-intervention rates, and length of hospital stay.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Oesophagectomy is a key component of curative treatment for oesophageal cancer. Minimally invasive and robotic-assisted techniques are increasingly used and are associated with improved postoperative recovery. However, these approaches may be associated with a higher incidence of postoperative chyle leak due to extensive mediastinal lymphatic dissection.
Chylothorax occurs when the thoracic duct or its tributaries are disrupted, resulting in leakage of lymphatic fluid into the pleural cavity. This complication can lead to prolonged hospitalisation, nutritional depletion, immunosuppression, and may require radiological or surgical intervention.
Standard postoperative care includes initiation of jejunostomy feeding on postoperative day 1 using enteral formulations containing long-chain triglycerides. These lipids are absorbed via chylomicron formation and transported through the lymphatic system, potentially increasing thoracic duct flow and chyle production.
Medium-chain triglycerides (MCTs), in contrast, are absorbed directly into the portal venous system and bypass the lymphatic circulation. MCT-based feeds are widely used in the management of established chyle leaks, but their prophylactic use has not been evaluated in prospective randomised studies.
This study is a prospective, single-centre, randomised controlled trial conducted at Beaumont Hospital. Adult patients undergoing minimally invasive or robotic-assisted oesophagectomy with placement of a feeding jejunostomy will be eligible for inclusion.
Participants will be randomised in a 1:1 ratio to receive either:
- Standard jejunostomy feeding (Nutrison Protein Plus 1.25 kcal/ml), or
- MCT-based jejunostomy feeding (Nutrison Peptisorb 1 kcal/ml)
Enteral feeding will commence on postoperative day 1 and follow an identical escalation protocol in both groups.
The primary endpoint is the incidence of clinically and biochemically confirmed chylothorax, defined according to Esophageal Complications Consensus Group criteria.
Secondary endpoints include:
- Chest drain output volume
- Requirement for re-intervention (radiological or surgical)
- Postoperative length of stay
- 90-day postoperative morbidity
A total of 160 participants will be enrolled. Analysis will be conducted on an intention-to-treat basis.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Prof jarlath Bolger, MB, BCh, BAO, MCh, FRCSI
- Numéro de téléphone: 018093000
- E-mail: jarbolger@rcsi.com
Lieux d'étude
-
-
Dublin
-
Beaumont, Dublin, Irlande, D09V2N0
- Recrutement
- Beaumont RCSI Cancer Centre
-
Contact:
- Aisling Hegarty, PhD
- Numéro de téléphone: 018093000
- E-mail: Aislinghegarty@rcsi.ie
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of oesophageal cancer (adenocarcinoma or squamous cell carcinoma)
- Planned minimally invasive or robotic-assisted oesophagectomy (MIO or RAMIO) with curative intent
- Placement of feeding jejunostomy at or prior to oesophagectomy
- Able to provide written informed consent
Exclusion Criteria:
- Inability to provide informed consent
- No feeding jejunostomy placed at or prior to surgery
- Prior or concomitant malignancy that would interfere with study protocol or outcomes
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Standard Jejunostomy Feeding
Participants randomised to this group will receive standard postoperative enteral nutrition via feeding jejunostomy beginning on postoperative day 1.
The standard formula used will be Nutrison Protein Plus 1.25 kcal/ml.
Feed initiation and escalation will follow the institution's established enhanced recovery protocol.
|
Postoperative enteral feeding using a standard long-chain triglyceride-based jejunostomy formula (Nutrison Protein Plus 1.25 kcal/ml), initiated on postoperative day 1 and escalated according to institutional feeding protocol.
|
|
Expérimental: Medium-Chain Triglyceride (MCT) Jejunostomy Feeding
Participants randomised to this group will receive medium-chain triglyceride (MCT)-based enteral nutrition via feeding jejunostomy beginning on postoperative day 1.
The formula used will be Nutrison Peptisorb 1 kcal/ml.
Feed initiation and escalation will follow the same protocol as the control group.
|
Postoperative enteral feeding using a medium-chain triglyceride-based jejunostomy formula (Nutrison Peptisorb 1 kcal/ml), initiated on postoperative day 1 and escalated according to institutional feeding protocol.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Clinically and Biochemically Confirmed Chylothorax
Délai: Postoperative days 1,3 and 5
|
Proportion of participants developing chylothorax following minimally invasive or robotic-assisted oesophagectomy. Chylothorax will be defined according to Esophageal Complications Consensus Group criteria as: Milky pleural effusion >200 mL in 24 hours after initiation of enteral feeding and/or Pleural fluid triglyceride level >100 mg/dL and/or Presence of chylomicrons in pleural fluid At least two diagnostic criteria must be present to confirm chylothorax. Diagnosis will be based on pleural fluid analysis collected on postoperative days 1, 3, and 5. |
Postoperative days 1,3 and 5
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 25-11
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .